Skip to main content
. 2016 Jul 22;16:41. doi: 10.1186/s12871-016-0210-5

Fig. 2.

Fig. 2

Incidence of nausea. Per- protocol analysis (a) and intention-to-treat analysis (b). *P < 0.05 versus placebo group, †P < 0.05 versus ondansetron group